A Pilot Study of Cultural/Racial Differences in Patient Perspectives on Long-Acting Injectable Antipsychotics for the Treatment of Schizophrenia.

Q4 Medicine Clinical Schizophrenia and Related Psychoses Pub Date : 2017-01-01 Epub Date: 2014-05-20 DOI:10.3371/CSRP.PORI.050614
Steven G Potkin, Rimal Bera, Anna Eramo, Gina Lau
{"title":"A Pilot Study of Cultural/Racial Differences in Patient Perspectives on Long-Acting Injectable Antipsychotics for the Treatment of Schizophrenia.","authors":"Steven G Potkin,&nbsp;Rimal Bera,&nbsp;Anna Eramo,&nbsp;Gina Lau","doi":"10.3371/CSRP.PORI.050614","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>Long-acting injectable (LAI) antipsychotics improve treatment outcomes in patients with schizophrenia but are often reserved for only the most severely affected or nonadherent. Studies show cultural/racial differences in prescribing. This pilot study examined prescriber-patient interactions and cultural/racial differences in perceptions of LAIs among patients.</p><p><strong>Methods: </strong>A linguist analyzed 120 prescriber-patient conversations representing selected patient cultural/racial subgroups (European American, African American, Latino American; n=40 each) to identify similarities and differences in conceptualization and attitudes toward LAIs.</p><p><strong>Results: </strong>Of 35 LAI-naive patients offered LAIs, 9% (3/35) responded favorably, 46% (16/35) were neutral/passive, and 46% (16/35) had concerns or viewed LAIs as unfavorable. Among LAI-naive patients, favorable or neutral/passive responses were reported for 50% (7/14) of European Americans, 63% (10/16) of African Americans, and 40% (2/5) of Latino Americans. The majority of LAI-naive patients (57% [20/35]) accepted LAI prescriptions, including 53% (17/32) of those who initially were neutral/passive or refused treatment (European American, 42% [5/12]; African American, 53% [8/15]; Latino American, 80% [4/5]). Fifty-seven percent (68/120) of patients expressed treatment goals. Goals of positive/negative symptom control were associated with positive attitudes toward LAIs while patients with goals focused on control of anxiety and insomnia tended to have negative attitudes toward LAIs. Latino-American patients who expressed treatment goals seemed more focused on discomfort control (67% [12/18]); goals of European Americans and African Americans were more equally distributed.</p><p><strong>Conclusions: </strong>Equal numbers of LAI-naive patients had unfavorable/concerned or neutral/passive attitudes toward treatment; relatively few patients responded favorably. The limited sample size precludes cultural/racial-specific conclusions.</p>","PeriodicalId":40019,"journal":{"name":"Clinical Schizophrenia and Related Psychoses","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2017-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"4","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Schizophrenia and Related Psychoses","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3371/CSRP.PORI.050614","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2014/5/20 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 4

Abstract

Objective: Long-acting injectable (LAI) antipsychotics improve treatment outcomes in patients with schizophrenia but are often reserved for only the most severely affected or nonadherent. Studies show cultural/racial differences in prescribing. This pilot study examined prescriber-patient interactions and cultural/racial differences in perceptions of LAIs among patients.

Methods: A linguist analyzed 120 prescriber-patient conversations representing selected patient cultural/racial subgroups (European American, African American, Latino American; n=40 each) to identify similarities and differences in conceptualization and attitudes toward LAIs.

Results: Of 35 LAI-naive patients offered LAIs, 9% (3/35) responded favorably, 46% (16/35) were neutral/passive, and 46% (16/35) had concerns or viewed LAIs as unfavorable. Among LAI-naive patients, favorable or neutral/passive responses were reported for 50% (7/14) of European Americans, 63% (10/16) of African Americans, and 40% (2/5) of Latino Americans. The majority of LAI-naive patients (57% [20/35]) accepted LAI prescriptions, including 53% (17/32) of those who initially were neutral/passive or refused treatment (European American, 42% [5/12]; African American, 53% [8/15]; Latino American, 80% [4/5]). Fifty-seven percent (68/120) of patients expressed treatment goals. Goals of positive/negative symptom control were associated with positive attitudes toward LAIs while patients with goals focused on control of anxiety and insomnia tended to have negative attitudes toward LAIs. Latino-American patients who expressed treatment goals seemed more focused on discomfort control (67% [12/18]); goals of European Americans and African Americans were more equally distributed.

Conclusions: Equal numbers of LAI-naive patients had unfavorable/concerned or neutral/passive attitudes toward treatment; relatively few patients responded favorably. The limited sample size precludes cultural/racial-specific conclusions.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
长期注射抗精神病药物治疗精神分裂症患者观点的文化/种族差异初步研究。
目的:长效注射(LAI)抗精神病药物可改善精神分裂症患者的治疗效果,但通常仅用于受影响最严重或不依从的患者。研究表明,处方存在文化/种族差异。这项初步研究考察了处方与患者之间的相互作用以及患者对LAIs认知的文化/种族差异。方法:一位语言学家分析了120个处方-患者对话,代表了选定的患者文化/种族亚群(欧洲裔美国人、非洲裔美国人、拉丁裔美国人;n=40(每个)),以确定对lai的概念化和态度的异同。结果:35例初次接受LAIs治疗的患者中,9%(3/35)反应良好,46%(16/35)为中性/被动,46%(16/35)有顾虑或认为LAIs是不利的。在lai初始患者中,50%(7/14)的欧洲美国人、63%(10/16)的非洲美国人和40%(2/5)的拉丁美洲人报告了良好或中性/被动反应。大多数LAI初治患者(57%[20/35])接受了LAI处方,其中53%(17/32)的患者最初是中性/被动或拒绝治疗(欧美,42% [5/12];非裔美国人53% [8/15];拉丁美洲,80%[4/5])。57%(68/120)的患者表达了治疗目标。以正/负症状控制为目标的患者对lai持积极态度,以控制焦虑和失眠为目标的患者对lai持消极态度。表达治疗目标的拉丁美洲患者似乎更关注不适控制(67% [12/18]);欧洲裔美国人和非洲裔美国人的目标分配更加平均。结论:相同数量的初次感染患者对治疗持不利/关注或中立/被动态度;相对较少的患者反应良好。有限的样本量排除了文化/种族特异性结论。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Clinical Schizophrenia and Related Psychoses
Clinical Schizophrenia and Related Psychoses Medicine-Psychiatry and Mental Health
自引率
0.00%
发文量
0
期刊介绍: The vision of the exciting new peer-reviewed quarterly publication Clinical Schizophrenia & Related Psychoses (CS) is to provide psychiatrists and other healthcare professionals with the latest research and advances in the diagnosis and treatment of schizophrenia and related psychoses. CS is a practice-oriented publication focused exclusively on the newest research findings, guidelines, treatment protocols, and clinical trials relevant to patient care.
期刊最新文献
Dysexecutive Behavior in First-Episode Schizophrenia. Dysexecutive Behavior in First-Episode Schizophrenia Grading meningiomas by used imaging features on magnetic resonance imaging The Association between Serum Levels of Ferritin and D-Dimer with Liver Function Tests in Patients with COVID-19 Role of Susceptibility Weighted Magnetic Resonance Imaging in Neurological Diagnosis
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1